ASCO 2024 Annual Meeting-Chicago USA May 31-June 4, 2024
Comprehensive molecular profiling in newly diagnosed advanced high-grade ovarian cancer: unveiling BRCA 1/2 mutations and Genomic Instability Scores to advocate for public insurance coverage of genetic testing – Insights from the Hellenic Society of Medical Oncology (HeSMO) national program
Emmanouil Saloustros, Michael Liontos, Eleni Timotheadou, Charalampos Andreadis, Efthymia Skafida, John Syrios, Antonia Kalykaki, Konstantinos Koutsoukos, Georgios Kesisis, Ioannis Boukovinas, Anastasios Boutis, Pavlos Papakotoulas, Dimitrios Ziogas, Sofia Karageorgopoulou, Stylianos Giassas, Evangelos Lianos, Natalia Chatzifoti, Fotini Papageorgiou, Zenia Saridaki
On behalf of the Hellenic Society of Medical Oncology (HeSMO), Athens, Greece
View abstract in Journal of Clinical Oncology
Background: Homologous recombination deficiency (HRD) in ovarian cancer, indicative of impaired DNA repair, contributes to genomic instability (GIS). Beyond mutations in BRCA1/2 genes, GIS is particularly significant for identifying patients who may benefit from PARP inhibitors. Equivalence between Myriad Genetics' myChoice CDx and the standard diagnostic tests OncoScan and Amoy Diagnostics has been published, prompting HeSMO to launch a national program addressing GIS and BRCA 1/2 mutations in newly diagnosed advanced high grade ovarian cancer patients, with the utilization of these more economically advantageous tests, in order to guide effective therapeutic strategies, since official reimbursement is not yet applicable in our country.
Methods: Patients with locally advanced or metastatic high-grade stage III/IV ovarian cancer were eligible for the HeSMO program, submitting an FFPE tissue tumor sample. The evaluation focused on HRD detection (positive or negative) and GIS assessment (high or low), combining results from OncoScan and Amoy Diagnostics.
Results: Between August 2022 and December 2023, 511 patients from Greece underwent testing. 48.14% (n=246) tested HRD positive, 46.58% (n=238) HRD negative. High GIS score was observed in 44.81% (n=229), low GIS in 49.71% (n=254). Potential pathogenic mutations in BRCA1/2 genes were found in 19.96% (n=102). BRCA1 mutations (13.70%, n=70) included key mutations: c.190T>C p.(Cys64Arg), c.3700_3704delGTAAA p.(Val1234GlnfsTer8), c.4065_4068del p.(Asn1355LysfsTer10). BRCA2 mutations (6.26%, n=32) comprised of c.1129G>T p.(Glu377Ter), c.3650_3659del p.(Arg1217IlefsTer8), c.7150C>T p.(Gln2384Ter). In 27 samples (5.28%) no result was produced.
Conclusions: HRD and GIS are vital genomic instability biomarkers in high-grade ovarian cancer. These metrics provide valuable insights into tumor aggressiveness, guiding therapeutic decisions, including the use of PARP inhibitors. In this study of 511 patients from 50 centers across Greece, 48.14% tested positive for HRD, emphasizing PARP inhibitors' significance and suggesting hereditary implications. Our commitment to enhance patient access to reliable diagnostic biomarker testing in Greece is unquestionable. Furthermore, we believe, our results will strengthen our efforts towards official state reimbursement, paving the way for local HRD testing solutions.
Table 1.